sensei(SNSE) - 2025 Q4 - Annual Report

Acquisition and Development - The company completed the acquisition of Faeth Therapeutics on February 17, 2026, which included a lead asset, PIKTOR, and received $200 million in gross proceeds from a private placement financing[15] - The acquisition of Faeth Therapeutics is expected to advance PIKTOR through key clinical milestones, supported by a broad syndicate of investors[15] - The company has not yet initiated an independent clinical trial of PIKTOR in ovarian or lung cancer, with future development dependent on regulatory discussions and ongoing trial results[102] Clinical Trials and Efficacy - PIKTOR is currently in a Phase 2 trial for second-line advanced endometrial cancer, with topline data expected by year-end 2026, and a Phase 1b trial for HR+/HER2- advanced breast cancer is planned to start in the first half of 2026[17] - The objective response rate (ORR) in the Phase 1b trial was 47%, with a clinical benefit rate (CBR) of 73% among evaluable patients[62] - Median progression-free survival (PFS) was reported at 11 months, while overall survival (OS) reached 17 months in the same trial[62] - PIKTOR demonstrated an 80% objective response rate (ORR) in five heavily pretreated endometrial cancer patients, with a median PFS of 11 months[88] - The ongoing Phase 2 trial of PIKTOR in endometrial cancer anticipates topline data by year-end 2026, with the last patient expected to be dosed in 2027[96] - The DICE trial showed a 34% decrease in risk of disease progression (HR=0.66) with the addition of sapanisertib to paclitaxel, with mean PFS of 5.8 months versus 4.0 months for paclitaxel alone[98] - PIKTOR's planned Phase 1b trial will evaluate escalating doses in advanced HR+/HER2- breast cancer, with interim data expected in 2027 and expansion cohorts in 2028[84] Mechanism and Targeting - The PI3K/AKT/mTOR pathway is dysregulated in up to 50% of all solid tumors, making it a significant target for cancer therapies[16] - PIKTOR is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway, potentially leading to deeper and more durable tumor suppression compared to single-node inhibitors[39] - PIKTOR's selective PI3Kα inhibition may reduce the risk of off-target toxicities associated with pan-PI3K inhibitors, enhancing its clinical profile[45] - PIKTOR's development targets significant unmet needs in oncogenesis and tumor progression related to dysregulated PI3K/AKT/mTOR pathway activity[65] Safety and Tolerability - PIKTOR demonstrated a tolerability profile with only one dose-limiting toxicity observed, and most adverse events were mild or moderate[63] - In the ongoing Phase 2 trial, stomatitis occurred in 13.6% of patients (0% grade 3/4) and hyperglycemia in 13.6% (4.5% grade 3/4)[64] - PIKTOR's combination therapy has been well tolerated in approximately 1,050 patients across multiple studies, with 152 patients receiving the drug[58] - The company believes PIKTOR may provide more comprehensive and tolerable PI3K/AKT/mTOR pathway inhibition than current therapies[59] Market Potential and Competition - The total addressable market for second-line HR+/HER2- breast cancer and advanced endometrial cancer in the U.S. is estimated to be approximately $6 billion, with HR+/HER2- breast cancer accounting for about $5 billion[148] - The company faces competition from various biotechnology and pharmaceutical firms, which may have greater financial resources and established market presence[108] - The competitive landscape includes several product candidates in clinical development that pose a direct threat to PIKTOR, particularly for advanced HR+/HER2- breast cancer[111] Regulatory and Compliance - The FDA requires the submission of an Investigational New Drug application (IND) before human clinical trials can begin, which becomes effective 30 days after receipt unless placed on clinical hold[151] - Clinical trials must be conducted in three phases: Phase 1 focuses on safety and dosage, Phase 2 evaluates efficacy and safety in a limited patient population, and Phase 3 provides substantial evidence of efficacy in a larger population[160] - The FDA aims to review a standard NDA for a new molecular entity within ten months from the filing date, with a typical review taking twelve months from submission[163] - The FDA may issue an approval letter for commercial marketing or a Complete Response Letter (CRL) detailing deficiencies in the NDA, which must be addressed before resubmission[165] - The FDA may require a risk evaluation and mitigation strategy (REMS) for approved drugs to ensure safe use, which could limit marketing and distribution[166] Financial Obligations and Royalties - The company is obligated to pay tiered single-digit royalties on annual net sales of Serabelisib Products, with obligations commencing on the first commercial sale[122] - The company is obligated to pay up to $119 million in development, regulatory, and commercial launch milestone payments, and up to $250 million in sales milestone payments for PIKTOR and related products[132] - The royalty payments for PIKTOR Products will commence on the first commercial sale and continue for up to 10 years or until the expiration of relevant patents, whichever is later[133] Intellectual Property - The patent portfolio for PIKTOR includes 13 issued U.S. patents and four pending U.S. applications, with expiration dates ranging from 2027 to 2046[114] - Intellectual property is crucial for the company, with efforts to protect and enhance proprietary technology through patents and trade secrets[112] Future Developments - The company is engaged in ongoing Chemistry, Manufacturing, and Controls (CMC) development to support potential future registrational trials and New Drug Application submissions[146] - The company has not yet established a commercial organization or distribution capabilities for its products, despite the substantial market potential[148]